Clas Malmeström

• Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.

  Igal Rosenstein, Anna Nordin, Hemin Sabir, Clas Malmeström, Kaj Blennow, Markus Axelsson, Lenka Novakova
  Journal of neurology - 2024
• Tyro3 and Gas6 are associated with white matter and myelin integrity in multiple sclerosis.

  Igal Rosenstein, Lenka Nováková Nyrén, Hlin Kvartsberg, Anna Nordin, Sofia Rasch, Elzbieta Rembeza, Sofia Sandgren, Clas Malmeström, Stefanie Fruhwürth, Markus Axelsson, Kaj Blennow, Henrik Zetterberg, Jan Lycke
  Journal of Neuroinflammation - 2024
• The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center study

  Sofia Sandgren, Lenka Novakova, Anna Nordin, Hemin Sabir, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke
  MULTIPLE SCLEROSIS AND RELATED DISORDERS - 2024
• Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain-Barré syndrome

  Brynhildur Hafsteinsdottir, Helen H. Farman, Nina Lagerstrom, Henrik Zetterberg, Oluf Andersen, Lenka Novakova, Bengt Nellgård, Hans Rosén, Clas Malmeström, Igal Rosenstein, Jan Lycke, Markus Axelsson
  JOURNAL OF NEUROLOGY - 2024
• Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study

  Magnus Johnsson, Y. T. Stenberg, H. H. Farman, Kaj Blennow, Henrik Zetterberg, Clas Malmeström, Sofia Sandgren, Igal Rosenstein, Jan Lycke, Markus Axelsson, Lenka Novakova
  MULTIPLE SCLEROSIS JOURNAL - 2024
• Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis

  Igal Rosenstein, Markus Axelsson, Lenka Novakova, Clas Malmeström, Kaj Blennow, Henrik Zetterberg, Jan Lycke
  Journal of Neurology - 2023
• A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis.

  Sofia Sandgren, Lenka Nováková Nyrén, Anna Nordin, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke
  Frontiers in neurology - 2023
• The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies

  M. Rabenstein, O. G. Thomas, G. Carlin, M. Khademi, K. A. Högelin, Clas Malmeström, Markus Axelsson, Anne Brandt, G. Gafvelin, H. Grönlund, I. Kockum, F. Piehl, Jan Lycke, T. Olsson, T. Hessa
  European Journal of Neurology - 2023
• Presence of neural surface and onconeural autoantibodies in cerebrospinal fluid and serum in neurological diseases presents a potential risk for misdiagnosis

  Oskar Stevens-Jones, Clas Malmeström, Clara Constantinescu, Keti Dalla, Bengt Nellgård, Johan Zelano, Radu Constantinescu, Markus Axelsson
  European Journal of Neurology - 2023
• Pregnancy outcomes for women with myasthenia gravis and their newborns: A nationwide register-based cohort study

  L. O'Connor, Clas Malmeström, R. D. Rodrigues, S. Brauner, A. K. Wikström, A. R. Punga
  European Journal of Neurology - 2023
• Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome: Epidemiology and Outcome of Neuronal Antibody Testing in Sweden

  S. Kosek, B. Persson, R. Rodrigues, Clas Malmeström, A. R. Punga, J. Burman
  ACTA NEUROLOGICA SCANDINAVICA - 2023
• The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey

  Sofia Sandgren, Lenka Novakova, Markus Axelsson, Firoozeh Amirbeagi, I. Kockum, T. Olsson, Clas Malmeström, Jan Lycke
  Frontiers in Neurology - 2023
• No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab

  Magnus Johnsson, Helen H. Farman, Kaj Blennow, Henrik Zetterberg, Clas Malmeström, Markus Axelsson, Jan Lycke
  Multiple Sclerosis Journal - 2022
• SARS-COV-2 a trigger of myelin oligodendrocyte glycoprotein-associated disorder

  Magnus Johnsson, Fredrik Asztely, S. Hejnebo, Markus Axelsson, Clas Malmeström, T. Olausson, Jan Lycke
  Annals of Clinical and Translational Neurology - 2022
• Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of life

  Clara Constantinescu, Lenka Novakova, Clas Malmeström, Radu Constantinescu, Markus Axelsson, Jan Lycke
  Multiple Sclerosis and Related Disorders - 2021
• Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: An observational study

  Christina Zhukovsky, Sofia Sandgren, Thomas Silfverberg, Sigrun Einarsdottir, Andreas Tolf, Anne Marie Landtblom, Lenka Novakova, Markus Axelsson, Clas Malmeström, Honar Cherif, Kristina Carlson, Jan Lycke, Joachim Burman
  Journal of Neurology, Neurosurgery and Psychiatry - 2021
• Ultrasensitive DNA Immune Repertoire Sequencing Using Unique Molecular Identifiers.

  Gustav Johansson, Melita Kaltak, Cristiana Rîmniceanu, Avadhesh Kumar Singh, Jan Lycke, Clas Malmeström, Michael Hühn, Outi Vaarala, Susanna Cardell, Anders Ståhlberg
  Clinical chemistry - 2020
• Inflammation-related plasma and CSF biomarkers for multiple sclerosis

  J. Huang, M. Khademi, L. Fugger, O. Lindhe, Lenka Novakova, Markus Axelsson, Clas Malmeström, Clara Constantinescu, Jan Lycke, F. Piehl, T. Olsson, I. Kockum
  Proceedings of the National Academy of Sciences of the United States of America - 2020
• NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS

  Lenka Novakova, M Axelsson, Clas Malmeström, Henrik Zetterberg, Kaj Blennow, A. Svenningsson, Jan Lycke
  Multiple Sclerosis and Related Disorders - 2020
• Intrathecal immunoreactivity in people with or without previous infectious mononucleosis.

  Daniel Jons, Henrik Zetterberg, Clas Malmeström, Tomas Bergström, Markus Axelsson, Kaj Blennow, Måns Thulin, Peter Sundström, Oluf Andersen
  Acta neurologica Scandinavica - 2020
• Cerebrospinal fluid CD4(+)/CD8(+)ratio in diagnosing neurosarcoidosis

  Sara Nordström, Bengt Andersson, Clas Malmeström
  Acta Neurologica Scandinavica - 2020
• Neuronal antibodies in adult patients with new-onset seizures: A prospective study

  Johan Zelano, Markus Axelsson, Radu Constantinescu, Clas Malmeström, E. Kumlien
  Brain and Behavior - 2019
• CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1

  Pontus Wasling, Clas Malmeström, Kaj Blennow
  Neurology, neuroimmunology & neuroinflammation - 2019
• Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies

  Markus Axelsson, N. Dubuisson, Lenka Novakova, Clas Malmeström, G. Giovannoni, Jan Lycke, S. Gnanapavan
  Acta Neurologica Scandinavica - 2019
• Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis.

  Åsa P Sandelius, Sofia Sandgren, Markus Axelsson, Clas Malmeström, Lenka Novakova, Vesna Kostanjevecki, Manu Vandijck, Kaj Blennow, Henrik Zetterberg, Jan Lycke
  Scientific reports - 2019
• Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS

  Lenka Novakova, Avadhesh Kumar Singh, Markus Axelsson, Marcus Ståhlman, Martin Adiels, Clas Malmeström, Henrik Zetterberg, Jan Borén, Jan Lycke, Susanna Cardell, Maria K. Blomqvist
  Journal of Neurochemistry - 2018
• Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers.

  Lenka Novakova, Markus Axelsson, Clas Malmeström, Henrik Imberg, Henrik Zetterberg, Olle Nerman, Jan Lycke
  PloS one - 2018
• Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.

  Lenka Nováková Nyrén, Markus Axelsson, Mohsen Khademi, Henrik Zetterberg, Kaj Blennow, Clas Malmeström, Fredrik Piehl, Tomas Olsson, Jan Lycke
  Journal of neurochemistry - 2017
• Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.

  Lenka Novakova, Henrik Zetterberg, Peter Sundström, Markus Axelsson, Martin Gunnarsson, Clas Malmeström, Fredrik Piehl, Kaj Blennow, Jan Lycke
  Neurology - 2017
• Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies.

  Radu Constantinescu, Fredrik Asztély, Filip Bergquist, Henrik Zetterberg, Ulf Andreasson, Markus Axelsson, Elinor Ben-Menachem, Daniel Jons, Clas Malmeström, Lars Rosengren, Kaj Blennow
  Journal of neuroimmunology - 2017
• Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.

  Lenka Novakova, Markus Axelsson, Mohsen Khademi, Henrik Zetterberg, Kaj Blennow, Clas Malmeström, Fredrik Piehl, Thomas Olsson, Jan Lycke
  Multiple sclerosis (Houndmills, Basingstoke, England) - 2017
• High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis.

  Avadhesh Kumar Singh, Lenka Novakova, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke, Susanna Cardell
  Frontiers in Immunology - 2017
• Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.

  Annika Öhrfelt, Markus Axelsson, Clas Malmeström, Lenka Novakova, Amanda Heslegrave, Kaj Blennow, Jan Lycke, Henrik Zetterberg
  Multiple sclerosis (Houndmills, Basingstoke, England) - 2016
• Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients

  P. Alping, T. Frisell, Lenka Novakova, P. Islam-Jakobsson, J. Salzer, A. Bjorck, Markus Axelsson, Clas Malmeström, K. Fink, Jan Lycke, A. Svenningsson, F. Piehl
  Annals of Neurology - 2016
• YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.

  Joachim Burman, Raili Raininko, Kaj Blennow, Henrik Zetterberg, Markus Axelsson, Clas Malmeström
  Journal of neuroimmunology - 2016
• Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis

  Radu Constantinescu, David Krysl, Filip Bergquist, Kerstin Andrén, Clas Malmeström, Fredrik Asztely, Markus Axelsson, Elinor Ben-Menachem, Kaj Blennow, Lars Rosengren, Henrik Zetterberg
  European Journal of Neurology - 2016
• Rituximab in multiple sclerosis

  J. Salzer, R. Svenningsson, P. Alping, Lenka Novakova, A. Björck, K. Fink, P. Islam-Jakobsson, Clas Malmeström, Markus Axelsson, M. Vågberg, P. Sundström, Jan Lycke, F. Piehl, A. Svenningsson
  Neurology - 2016
• Upper Respiratory Infections and MRI Activity in Relapsing-Remitting Multiple Sclerosis

  Maria Kneider, Vera Lisovskaja, Jan Lycke, Clas Malmeström, Johannes Jakobsen, Olle Nerman, Oluf Andersen
  Neuroepidemiology - 2015
• Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.

  Lenka Novakova, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Ingemar Björkhem, Virginija Danylaité Karrenbauer, Jan Lycke
  Journal of the Neurological Sciences - 2015
• Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study

  J. Kuhle, G. Disanto, R. Dobson, R. Adiutori, L. Bianchi, J. Topping, J. P. Bestwick, U. C. Meier, M. Marta, G. Dalla Costa, T. Runia, E. Evdoshenko, N. Lazareva, E. Thouvenot, P. Iaffaldano, V. Direnzo, M. Khademi, F. Piehl, M. Comabella, M. Sombekke, J. Killestein, H. Hegen, S. Rauch, S. D'Alfonso, J. C. Alvarez-Cermeno, P. Kleinova, D. Horakova, R. Roesler, F. Lauda, S. Llufriu, T. Avsar, U. Uygunoglu, A. Altintas, S. Saip, T. Menge, C. Rajda, R. Bergamaschi, N. Moll, M. Khalil, R. Marignier, I. Dujmovic, H. Larsson, Clas Malmeström, E. Scarpini, C. Fenoglio, S. Wergeland, A. Laroni, V. Annibali, S. Romano, A. D. Martinez, A. Carra, M. Salvetti, A. Uccelli, O. Torkildsen, K. M. Myhr, D. Galimberti, K. Rejdak, Jan Lycke, J. L. Frederiksen, J. Drulovic, C. Confavreux, D. Brassat, C. Enzinger, S. Fuchs, I. Bosca, J. Pelletier, C. Picard, E. Colombo, D. Franciotta, T. Derfuss, R. L. P. Lindberg, O. Yaldizli, L. Vecsei, B. C. Kieseier, H. P. Hartung, P. Villoslada, A. Siva, A. Saiz, H. Tumani, E. Havrdova, L. M. Villar, M. Leone, N. Barizzone, F. Deisenhammer, C. Teunissen, X. Montalban, M. Tintore, T. Olsson, M. Trojano, S. Lehmann, G. Castelnovo, S. Lapin, R. Hintzen, L. Kappos, R. Furlan, V. Martinelli, G. Comi, S. V. Ramagopalan, G. Giovannoni
  Multiple Sclerosis Journal - 2015
• Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

  Markus Axelsson, Clas Malmeström, Martin Gunnarsson, Henrik Zetterberg, Peter Sundström, Jan Lycke, Anders Svenningsson
  Multiple sclerosis (Houndmills, Basingstoke, England) - 2014
• First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS.

  Clas Malmeström, Bengt A. Andersson, Jan Lycke
  Journal of neurology - 2014
• CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment.

  Clas Malmeström, Markus Axelsson, Jan Lycke, Henrik Zetterberg, Kaj Blennow, Bob Olsson
  Journal of neuroimmunology - 2014
• MS risk genes are transcriptionally regulated in CSF leukocytes at relapse

  Margareta Jernås, Clas Malmeström, Markus Axelsson, Caroline Olsson, Intawat Nookaew, Hans Wadenvik, Henrik Zetterberg, Kaj Blennow, Jan Lycke, Mats Rudemo, Bob Olsson
  Multiple sclerosis (Houndmills, Basingstoke, England) - 2013
• The impact of rituximab therapy in multiple sclerosis on cerebrospinal fluid cell gene expression

  Margareta Jernås, Clas Malmeström, Intawat Nookaew, Hans Wadenvik, Bob Olsson, Jan Lycke
  Multiple Sclerosis Journal: 29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS - 2013
• The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.

  Markus Axelsson, Niklas Mattsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke
  Journal of Neuroimmunology - 2013
• Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

  J Kuhle, Clas Malmeström, Markus Axelsson, K Plattner, O Yaldizli, T Derfuss, G Giovannoni, L Kappos, Jan Lycke
  Acta neurologica Scandinavica - 2013
• Serum levels of LIGHT in MS

  Clas Malmeström, Alan Gillett, Margareta Jernås, Mohsen Khademi, Markus Axelsson, Ingrid Kockum, Niklas Mattsson, Henrik Zetterberg, Kaj Blennow, Lars Alfredsson, Hans Wadenvik, Jan Lycke, Tomas Olsson, Bob Olsson
  Multiple sclerosis (Houndmills, Basingstoke, England) - 2013
• Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

  Helen Tedeholm, Jan Lycke, Bengt Skoog, Vera Lisovskaja, J Hillert, C Dahle, J Fagius, S Fredrikson, A-M Landtblom, Clas Malmeström, C Martin, F Piehl, Björn Runmarker, L Stawiarz, M Vrethem, Olle Nerman, Oluf Andersen
  Multiple Sclerosis Journal - 2013
• Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.

  Kristin Augutis, Markus Axelsson, Erik Portelius, Gunnar Brinkmalm, Ulf Andreasson, Mikael K Gustavsson, Clas Malmeström, Jan Lycke, Kaj Blennow, Henrik Zetterberg, Niklas Mattsson
  Multiple sclerosis (Houndmills, Basingstoke, England) - 2013

More publications

We have limited the number of publications on this page. Visit GUP (The Publication Database for Gothenburg University) to find more publications.